In a second study presented.

‘.. In a second study presented , Dr., Dr. Igho Onakpoya the Peninsula Medical School at the Universities of Exeter and Plymouth, they can review of all existing systematic reviews of clinical trials on weight loss supplements. The analysis summarizes the state of evidence from reviews of studies involving nine popular slimming supplements, including chromium picolinate, Ephedra, bitter orange, conjugated linoleic acid , calcium, guar gum, glucomannan, chitosan and green tea. ‘We have no evidence that any of these supplements is studied an adequate treatment for reducing body weight found ‘Onakpoya said. ‘Annual global sales of dietary supplements are well over $ 13 billion.

Researchers have the supplements from German pharmacies, changed the packaging and product names to make them look neutral and wrote the information leaflet inserts the product name the product name from the text. They then gave 189 obese or overweight middle-aged consumers packages either fake pills or one of the nine supplements, each week for eight weeks in doses recommended by the manufacturers. Some of the products came with dietary advice, while others not, the researchers provided exactly the same advice as in the relevant product brochures written.

Onakpoya said some of the supplements included the study were reported to cause some side effects, however rigorous research is needed, he said, because few studies have duration duration and the number of patients in most studies were small – together together the conclusions about the efficacy and safety can be drawn, such supplements..Last year published in Dandekar the Team a study from HIV-infected patients despite of the lack of the treatment, over 10 years were survives on a healthy level of T-cells and suppresses viral load. – ‘We looked at their nice lymphoid and did not see loss of T – cells are correlates this with better clinical results that. ‘Dandekar discussed.

This press release contains forward-looking Information regarding a product candidates who by the United States by which United States Food and Drug Administration and which European Medicines Evaluation Agency, the significant risks and uncertainties. Such risks and uncertainties include , among other things, whether or or when such a regulatory authorities approval the product candidate, December 2004, and labeling and other matters commercial potential of the commercial potential as well as competitive developments.

You Might Also Like